A study of AβPP transgenic mice showed no particular association between mGluR5 availability in vivo with Alzheimer’s disease model pathology, although post-mortem immunoblotting showed increases in mGluR5 protein levels that had been invisible to PET [162]. This evidence concerns the gene GRM5 and early-onset autosomal dominant Alzheimer disease.